View Future GrowthBone Biologics 과거 순이익 실적과거 기준 점검 0/6Bone Biologics의 수입은 연평균 -21.4%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 33.8% 증가했습니다.핵심 정보-21.38%순이익 성장률114.52%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률-61.20%순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 15hBone Biologics Corporation Achieves 29-Month Validated Shelf Life for rhNELL-1Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the Company progresses rhNELL-1 toward the manufacturing scale required for a future pivotal study. The Company previously stated its objective of achieving a shelf life sufficient to support scaled manufacturing ahead of a pivotal study. The 29-month validation is expected to bring the program meaningfully closer to that threshold. NB1, the Company's lead product candidate, combines rhNELL-1 protein with demineralized bone matrix to provide controlled bone regeneration. Bone Biologics is currently conducting a multicenter, prospective, randomized pilot clinical study evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion in Australia.New Risk • Sep 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (498% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.72m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.5m net loss next year).공시 • Jun 28Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $4 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 1,250,000 Security Name: Series D Warrants Security Type: Equity Warrant Securities Offered: 1,250,000 Security Name: Series E Warrants Security Type: Equity Warrant Securities Offered: 1,250,000공시 • Jun 27Bone Biologics Corporation Files Patent Application for Bone Regeneration TechnologyBone Biologics Corporation announced the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio and support the Company's strategic plan to advance the clinical development program.공시 • Jun 25Bone Biologics Corporation has filed a Follow-on Equity Offering.Bone Biologics Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 846,023 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 846,023 Security Name: Series D Warrants Security Type: Equity Warrant Securities Offered: 846,023 Security Name: Series E Warrants Security Type: Equity Warrant Securities Offered: 846,023New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.47m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change).New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.42m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year).New Risk • May 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (272% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.39m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$3.8m net loss next year).공시 • Apr 12Bone Biologics Corporation Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid PriceOn April 7, 2025, Bone Biologics Corporation (the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price requirement. If the Company evidences a closing bid price of at least $1 per share for a minimum of 10 consecutive business days during the 180-day compliance period, the Company will regain compliance. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company's common stock on Nasdaq. The Company intends to monitor the closing bid price of its common stock and consider its available options in the event the closing bid price of its common stock remains below $1 per share. The Company intends to seek stockholder approval for a reverse stock split of its outstanding common stock at its upcoming annual meeting of stockholders. If the closing bid price of the common stock remains below $1 per share and the stockholders approve the proposal, the Company's Board of Directors may authorize a reverse stock split to attempt to increase the per share price of the common stock and regain compliance with the Nasdaq Listing Standards.공시 • Apr 04Bone Biologics Corporation, Annual General Meeting, May 30, 2025Bone Biologics Corporation, Annual General Meeting, May 30, 2025.New Risk • Nov 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (44% average weekly change). Shareholders have been substantially diluted in the past year (435% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.50m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years).공시 • Oct 21Bone Biologics Corporation Appoints Phillip Meikle to Board of DirectorsBone Biologics Corporation announced the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He has broad experience representing diverse and innovative orthopedic and spine industry companies in developing and distributing innovative products. Mr. Meikle has been a consultant to Stryker Spine for the past five years. Biosystems of New England served as a distributor for Stryker Spine from 2002 to 2019, and for Medtronic Spine from 1992 to 2002. Mr. Meikle holds a B.S. from West Virginia University College of Engineering. He has received numerous professional awards including Inaugural Inductee in the Stryker Spine Hall of Fame and Distributor of the year at both Stryker and Medtronic Danek Spine.공시 • Oct 07Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective ImmediatelyOn October 1, 2024, Don Hankey informed Bone Biologics Corporation of his resignation as a director of the Company effective immediately. Mr. Hankey’s departure was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company is appreciative of Mr. Hankey’s years of service to the Company as a director.공시 • Sep 28Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Aug 09Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024. Location: 2 burlington woods drive, ste 100, ma 01803, burlington United StatesNew Risk • Jul 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.38m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years).공시 • Jun 21Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine FusionBone Biologics Corporation announced that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD) and will evaluate safety and effectiveness, fusion success, pain, function improvement and adverse events. To be enrolled in the study, patients must have DDD at one level from L2-S1 and may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level. These two patients were treated in Australia. The study design was previously reviewed and agreed upon by the U.S. Food and Drug Administration’s Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States. Lumbar DDD is one of the most common causes of low back pain. DDD also leads to substantial disability, with many patients suffering from decreased ability to walk, sit, stand and/or sleep. For some people, DDD is part of the natural process of growing older and is a significant medical issue that is increasing as the global population ages.공시 • Mar 05Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 119,000 Price\Range: $2.56 Discount Per Security: $0.1792 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 781,251 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 662,251 Price\Range: $2.559 Discount Per Security: $0.1792공시 • Mar 04Bone Biologics Corporation has completed a Follow-on Equity Offering.Bone Biologics Corporation has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 781,251 Price\Range: $2.56 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 781,251New Risk • Feb 23New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.92m market cap).공시 • Jan 31Bone Biologics Corporation has filed a Follow-on Equity Offering.Bone Biologics Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Prefunded Warrants Security Type: Equity Warrant Security Name: Common Warrants Security Type: Equity Warrant공시 • Jan 11Bone Biologics Corporation Announces Board ChangesBone Biologics Corporation announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon’s appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RNA processing to address hard-to-drug disease drivers. Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. He served as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. He was Chief Business Officer and Chief Financial Officer at Verastem Oncology. Before that, he was Chief Financial Officer at Harvard Bioscience Inc. Mr. Gagnon served as Executive Vice President, Chief Financial Officer, and Treasurer at Clean Harbors Inc. as well as Chief Accounting Officer and Controller at Biogen Idec Inc.Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an MBA from the MIT Sloan School of Management and a BA in Accounting from Bentley College. Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.공시 • Jan 10Bone Biologics Regains Compliance with Nasdaq Continued Listing RequirementsBone Biologics Corporation announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics was notified by Nasdaq on September 27, 2023 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on January 4, 2024, the 10th consecutive trading day when the closing bid price of the Company's common stock was over $1.00.공시 • Nov 21Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,139,063 Price\Range: $0.64 Discount Per Security: $0.0448 Transaction Features: Registered Direct Offering공시 • Nov 18Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,139,063 Price\Range: $0.64 Transaction Features: Registered Direct Offering공시 • Oct 01Bone Biologics Corporation Receives Non-Compliance Notice From NasdaqOn September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Accordingly, the Nasdaq staff has determined to delist the Company’s securities from Nasdaq (the “Staff Determination”). The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), to appeal the Staff Determination, which request will stay any delisting action pending the issuance of the Panel’s determination. At the hearing, the Company expects to present its plan for regaining and sustaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company any additional time to regain compliance or that the Company will ultimately regain and sustain compliance for listing of its securities on Nasdaq. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform. The Company is evaluating several alternatives to regain compliance with the minimum bid price requirement.New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.55m market cap).공시 • Aug 04Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023, at 11:00 US Eastern Standard Time. Location: 2 Burlington Woods Drive, Ste 100, Burlington MA 01803 Burlington Massachusetts United States Agenda: To consider elect four directors to our Board of Directors; to consider executive officer compensation; to consider approve, in an advisory (non-binding) vote, the frequency of future advisory votes on executive officer compensation; to consider ratify the appointment of Weinberg & Company, P.A., as our independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider approve an amendment to our 2015 Equity Incentive Plan; and to consider other matters.New Risk • Jun 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.19m market cap).분석 기사 • Jun 07Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • May 22Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price RequirementBone Biologics Corporation announced that as previously disclosed on November 21, 2022 in the Current Report on Form 8-K filed by the company, on November 17, 2022, the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business day period, the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and that it had been provided a 180-calendar day grace period to regain compliance with that requirement, which period expired May 16, 2023. The Company was not eligible to obtain an additional second 180 calendar period to regain compliance because as of March 31, 2023, the Company did not meet the initial listing standard for stockholders equity. On May 18, 2023, the Company was notified by the Staff that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as of May 30, 2023, the Company’s securities, common stock and publically traded warrants, were subject to delisting unless the Company timely appeals the Staff’s determination by requesting a hearing before the Nasdaq Hearings Panel (the ‘Panel’). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of the Panel’s decision following the hearing and the expiration of any extension that may be granted by the Panel. In connection with regaining compliance, on May 1, 2023, the Company received the approval of the requisite number of holders of the shares of its common stock to amend its certificate of incorporation to effect a reverse split of the shares of its common stock at a ratio of 1-for-20 to 1-for-50 (or any number in between), with the exact ratio to be set within such range in the discretion of the Company’s board of directors without further approval or authorization of the Company’s stockholders. The Company believes that the reverse split should increase its bid price such that the Company meets the minimum bid requirement. Once the Company regains compliance with the minimum bid request, the Company will then be subject to the continuing listing requirements regarding stockholders equity which the Company currently satisfies. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform.공시 • Dec 24Bone Biologics Corporation Resigns Stephen Laneve as DirectorEffective December 18, 2022 Stephen LaNeve resigned as a director of the Bone Biologics Corporation. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.공시 • Nov 22Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price RequirementOn November 17, 2022, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until May 16, 2023, to regain compliance with the minimum closing bid price requirement. If the Company does not regain compliance during the compliance period ending May 16, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum closing bid price requirement, and (ii) notify Nasdaq of its intent to cure the deficiency. The Company can achieve compliance with the minimum closing bid price requirement if, during either compliance period, the minimum closing bid price per share of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days. The Company anticipates that its shares of common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period(s). The Company plans to carefully assess potential actions to regain compliance. However, the Company may be unable to regain compliance with the minimum closing bid price requirement during the compliance period(s), in which case the Company anticipates Nasdaq would provide a notice to the Company that its shares of common stock are subject to delisting, and the Company’s common shares would thereupon be delisted.Price Target Changed • Nov 16Price target decreased to US$4.88Down from US$7.90, the current price target is an average from 2 analysts. New target price is 1,416% above last closing price of US$0.32. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.16 last year.Price Target Changed • Oct 22Price target decreased to US$4.88Down from US$7.90, the current price target is an average from 2 analysts. New target price is 823% above last closing price of US$0.53. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$0.36 next year compared to a net loss per share of US$0.16 last year.공시 • Oct 14Bone Biologics Corporation has completed a Composite Units Offering.Bone Biologics Corporation has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Preferred Unit Securities Offered: 3,777,778 Price\Range: $1.35공시 • Oct 08Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,777,778 Price\Range: $1.35Seeking Alpha • Oct 07Bone Biologics prices $5.1M underwritten public offeringOrthobiologic products company Bone Biologics (NASDAQ:BBLG) priced an underwritten public offering of 3.8M units of securities at $1.35 per unit. The total gross proceeds stood at $5.1M, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share, one series A warrant to purchase one share at an exercise price equal to $1.62 per share, one series B warrant to purchase one share at an exercise price equal to $1.35 per share and one series C warrant to purchase one share at an exercise price equal to $2.16 per share. The shares and the warrants are immediately separable and will be issued separately, but will be purchased together in this offering. The warrants expire five years from the date of issuance. Additionally, the underwriters are granted a 45-day option to purchase up to 566,666 additional shares and/or 566,666 additional warrants. The offering is expected to close on or about Oct. 11. BBLG shares were trading -26.73% pre-market. Source: Press Release공시 • Jul 07Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022, at 11:00 US Eastern Standard Time. Location: at Bone Biologics Corporation offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803 Burlington United States Agenda: To elect five directors to Board of Directors; to approve, in an advisory (non-binding) vote, our executive officer compensation; to ratify the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year ending December 31, 2022; and to transact any other business as may properly come before the meeting or at any adjournment thereof.분석 기사 • Mar 18We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Bruce Stroever was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.매출 및 비용 세부 내역Bone Biologics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:BBLG 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-32131 Dec 250-32130 Sep 250-42230 Jun 250-72231 Mar 250-72231 Dec 240-72230 Sep 240-72130 Jun 240-52331 Mar 240-63531 Dec 230-93730 Sep 230-72730 Jun 230-62631 Mar 230-52431 Dec 220-12230 Sep 220-32130 Jun 220-22031 Mar 220-22031 Dec 210-21030 Sep 210-21030 Jun 210-21031 Mar 210-20031 Dec 200-20030 Sep 200-20030 Jun 200-21031 Mar 200-31131 Dec 190-31130 Sep 190-42230 Jun 190-42131 Mar 190-43031 Dec 180-43030 Sep 180-63030 Jun 180-83131 Mar 180-64-231 Dec 170-74-130 Sep 170-147030 Jun 170-167331 Mar 170-228831 Dec 160-2691230 Sep 160-24101230 Jun 160-23111031 Mar 160-199831 Dec 150-148430 Sep 150-741양질의 수익: BBLG 은(는) 현재 수익성이 없습니다.이익 마진 증가: BBLG는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BBLG은 수익성이 없으며 지난 5년 동안 손실이 연평균 21.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BBLG의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BBLG은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BBLG는 현재 수익성이 없으므로 자본 수익률이 음수(-61.2%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 13:29종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bone Biologics Corporation는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bradley SorensenZacks Small-Cap Research
공시 • 15hBone Biologics Corporation Achieves 29-Month Validated Shelf Life for rhNELL-1Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the Company progresses rhNELL-1 toward the manufacturing scale required for a future pivotal study. The Company previously stated its objective of achieving a shelf life sufficient to support scaled manufacturing ahead of a pivotal study. The 29-month validation is expected to bring the program meaningfully closer to that threshold. NB1, the Company's lead product candidate, combines rhNELL-1 protein with demineralized bone matrix to provide controlled bone regeneration. Bone Biologics is currently conducting a multicenter, prospective, randomized pilot clinical study evaluating NB1 in up to 30 subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion in Australia.
New Risk • Sep 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (498% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.72m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$4.5m net loss next year).
공시 • Jun 28Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,250,000 Price\Range: $4 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 1,250,000 Security Name: Series D Warrants Security Type: Equity Warrant Securities Offered: 1,250,000 Security Name: Series E Warrants Security Type: Equity Warrant Securities Offered: 1,250,000
공시 • Jun 27Bone Biologics Corporation Files Patent Application for Bone Regeneration TechnologyBone Biologics Corporation announced the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio and support the Company's strategic plan to advance the clinical development program.
공시 • Jun 25Bone Biologics Corporation has filed a Follow-on Equity Offering.Bone Biologics Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 846,023 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 846,023 Security Name: Series D Warrants Security Type: Equity Warrant Securities Offered: 846,023 Security Name: Series E Warrants Security Type: Equity Warrant Securities Offered: 846,023
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.47m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.42m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year).
New Risk • May 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.1m free cash flow). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (272% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.39m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$3.8m net loss next year).
공시 • Apr 12Bone Biologics Corporation Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid PriceOn April 7, 2025, Bone Biologics Corporation (the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 6, 2025, in which to regain compliance with the minimum bid price requirement. If the Company evidences a closing bid price of at least $1 per share for a minimum of 10 consecutive business days during the 180-day compliance period, the Company will regain compliance. If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The notification has no immediate effect on the listing of the Company's common stock on Nasdaq. The Company intends to monitor the closing bid price of its common stock and consider its available options in the event the closing bid price of its common stock remains below $1 per share. The Company intends to seek stockholder approval for a reverse stock split of its outstanding common stock at its upcoming annual meeting of stockholders. If the closing bid price of the common stock remains below $1 per share and the stockholders approve the proposal, the Company's Board of Directors may authorize a reverse stock split to attempt to increase the per share price of the common stock and regain compliance with the Nasdaq Listing Standards.
공시 • Apr 04Bone Biologics Corporation, Annual General Meeting, May 30, 2025Bone Biologics Corporation, Annual General Meeting, May 30, 2025.
New Risk • Nov 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$4.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.8m free cash flow). Share price has been highly volatile over the past 3 months (44% average weekly change). Shareholders have been substantially diluted in the past year (435% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.50m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years).
공시 • Oct 21Bone Biologics Corporation Appoints Phillip Meikle to Board of DirectorsBone Biologics Corporation announced the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He has broad experience representing diverse and innovative orthopedic and spine industry companies in developing and distributing innovative products. Mr. Meikle has been a consultant to Stryker Spine for the past five years. Biosystems of New England served as a distributor for Stryker Spine from 2002 to 2019, and for Medtronic Spine from 1992 to 2002. Mr. Meikle holds a B.S. from West Virginia University College of Engineering. He has received numerous professional awards including Inaugural Inductee in the Stryker Spine Hall of Fame and Distributor of the year at both Stryker and Medtronic Danek Spine.
공시 • Oct 07Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective ImmediatelyOn October 1, 2024, Don Hankey informed Bone Biologics Corporation of his resignation as a director of the Company effective immediately. Mr. Hankey’s departure was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company is appreciative of Mr. Hankey’s years of service to the Company as a director.
공시 • Sep 28Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Aug 09Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024. Location: 2 burlington woods drive, ste 100, ma 01803, burlington United States
New Risk • Jul 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.5m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.38m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$3.9m net loss in 2 years).
공시 • Jun 21Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine FusionBone Biologics Corporation announced that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD) and will evaluate safety and effectiveness, fusion success, pain, function improvement and adverse events. To be enrolled in the study, patients must have DDD at one level from L2-S1 and may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level. These two patients were treated in Australia. The study design was previously reviewed and agreed upon by the U.S. Food and Drug Administration’s Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States. Lumbar DDD is one of the most common causes of low back pain. DDD also leads to substantial disability, with many patients suffering from decreased ability to walk, sit, stand and/or sleep. For some people, DDD is part of the natural process of growing older and is a significant medical issue that is increasing as the global population ages.
공시 • Mar 05Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 119,000 Price\Range: $2.56 Discount Per Security: $0.1792 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 781,251 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 662,251 Price\Range: $2.559 Discount Per Security: $0.1792
공시 • Mar 04Bone Biologics Corporation has completed a Follow-on Equity Offering.Bone Biologics Corporation has completed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 781,251 Price\Range: $2.56 Security Name: Common Warrants Security Type: Equity Warrant Securities Offered: 781,251
New Risk • Feb 23New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.92m market cap).
공시 • Jan 31Bone Biologics Corporation has filed a Follow-on Equity Offering.Bone Biologics Corporation has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Prefunded Warrants Security Type: Equity Warrant Security Name: Common Warrants Security Type: Equity Warrant
공시 • Jan 11Bone Biologics Corporation Announces Board ChangesBone Biologics Corporation announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon’s appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RNA processing to address hard-to-drug disease drivers. Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. He served as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. He was Chief Business Officer and Chief Financial Officer at Verastem Oncology. Before that, he was Chief Financial Officer at Harvard Bioscience Inc. Mr. Gagnon served as Executive Vice President, Chief Financial Officer, and Treasurer at Clean Harbors Inc. as well as Chief Accounting Officer and Controller at Biogen Idec Inc.Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP. He holds an MBA from the MIT Sloan School of Management and a BA in Accounting from Bentley College. Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.
공시 • Jan 10Bone Biologics Regains Compliance with Nasdaq Continued Listing RequirementsBone Biologics Corporation announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq’s discretionary panel monitor until June 28, 2024. Bone Biologics was notified by Nasdaq on September 27, 2023 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on January 4, 2024, the 10th consecutive trading day when the closing bid price of the Company's common stock was over $1.00.
공시 • Nov 21Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,139,063 Price\Range: $0.64 Discount Per Security: $0.0448 Transaction Features: Registered Direct Offering
공시 • Nov 18Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,139,063 Price\Range: $0.64 Transaction Features: Registered Direct Offering
공시 • Oct 01Bone Biologics Corporation Receives Non-Compliance Notice From NasdaqOn September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Accordingly, the Nasdaq staff has determined to delist the Company’s securities from Nasdaq (the “Staff Determination”). The Company plans to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), to appeal the Staff Determination, which request will stay any delisting action pending the issuance of the Panel’s determination. At the hearing, the Company expects to present its plan for regaining and sustaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company any additional time to regain compliance or that the Company will ultimately regain and sustain compliance for listing of its securities on Nasdaq. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform. The Company is evaluating several alternatives to regain compliance with the minimum bid price requirement.
New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.55m market cap).
공시 • Aug 04Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023, at 11:00 US Eastern Standard Time. Location: 2 Burlington Woods Drive, Ste 100, Burlington MA 01803 Burlington Massachusetts United States Agenda: To consider elect four directors to our Board of Directors; to consider executive officer compensation; to consider approve, in an advisory (non-binding) vote, the frequency of future advisory votes on executive officer compensation; to consider ratify the appointment of Weinberg & Company, P.A., as our independent registered public accounting firm for the fiscal year ending December 31, 2023; to consider approve an amendment to our 2015 Equity Incentive Plan; and to consider other matters.
New Risk • Jun 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.19m market cap).
분석 기사 • Jun 07Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • May 22Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price RequirementBone Biologics Corporation announced that as previously disclosed on November 21, 2022 in the Current Report on Form 8-K filed by the company, on November 17, 2022, the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business day period, the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and that it had been provided a 180-calendar day grace period to regain compliance with that requirement, which period expired May 16, 2023. The Company was not eligible to obtain an additional second 180 calendar period to regain compliance because as of March 31, 2023, the Company did not meet the initial listing standard for stockholders equity. On May 18, 2023, the Company was notified by the Staff that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as of May 30, 2023, the Company’s securities, common stock and publically traded warrants, were subject to delisting unless the Company timely appeals the Staff’s determination by requesting a hearing before the Nasdaq Hearings Panel (the ‘Panel’). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of the Panel’s decision following the hearing and the expiration of any extension that may be granted by the Panel. In connection with regaining compliance, on May 1, 2023, the Company received the approval of the requisite number of holders of the shares of its common stock to amend its certificate of incorporation to effect a reverse split of the shares of its common stock at a ratio of 1-for-20 to 1-for-50 (or any number in between), with the exact ratio to be set within such range in the discretion of the Company’s board of directors without further approval or authorization of the Company’s stockholders. The Company believes that the reverse split should increase its bid price such that the Company meets the minimum bid requirement. Once the Company regains compliance with the minimum bid request, the Company will then be subject to the continuing listing requirements regarding stockholders equity which the Company currently satisfies. In the event the Company’s securities are delisted from Nasdaq, the Company expects that its securities should be eligible to trade on the over-the-counter OTC Markets platform.
공시 • Dec 24Bone Biologics Corporation Resigns Stephen Laneve as DirectorEffective December 18, 2022 Stephen LaNeve resigned as a director of the Bone Biologics Corporation. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
공시 • Nov 22Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price RequirementOn November 17, 2022, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until May 16, 2023, to regain compliance with the minimum closing bid price requirement. If the Company does not regain compliance during the compliance period ending May 16, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum closing bid price requirement, and (ii) notify Nasdaq of its intent to cure the deficiency. The Company can achieve compliance with the minimum closing bid price requirement if, during either compliance period, the minimum closing bid price per share of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days. The Company anticipates that its shares of common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period(s). The Company plans to carefully assess potential actions to regain compliance. However, the Company may be unable to regain compliance with the minimum closing bid price requirement during the compliance period(s), in which case the Company anticipates Nasdaq would provide a notice to the Company that its shares of common stock are subject to delisting, and the Company’s common shares would thereupon be delisted.
Price Target Changed • Nov 16Price target decreased to US$4.88Down from US$7.90, the current price target is an average from 2 analysts. New target price is 1,416% above last closing price of US$0.32. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.42 next year compared to a net loss per share of US$0.16 last year.
Price Target Changed • Oct 22Price target decreased to US$4.88Down from US$7.90, the current price target is an average from 2 analysts. New target price is 823% above last closing price of US$0.53. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$0.36 next year compared to a net loss per share of US$0.16 last year.
공시 • Oct 14Bone Biologics Corporation has completed a Composite Units Offering.Bone Biologics Corporation has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Preferred Unit Securities Offered: 3,777,778 Price\Range: $1.35
공시 • Oct 08Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,777,778 Price\Range: $1.35
Seeking Alpha • Oct 07Bone Biologics prices $5.1M underwritten public offeringOrthobiologic products company Bone Biologics (NASDAQ:BBLG) priced an underwritten public offering of 3.8M units of securities at $1.35 per unit. The total gross proceeds stood at $5.1M, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share, one series A warrant to purchase one share at an exercise price equal to $1.62 per share, one series B warrant to purchase one share at an exercise price equal to $1.35 per share and one series C warrant to purchase one share at an exercise price equal to $2.16 per share. The shares and the warrants are immediately separable and will be issued separately, but will be purchased together in this offering. The warrants expire five years from the date of issuance. Additionally, the underwriters are granted a 45-day option to purchase up to 566,666 additional shares and/or 566,666 additional warrants. The offering is expected to close on or about Oct. 11. BBLG shares were trading -26.73% pre-market. Source: Press Release
공시 • Jul 07Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022, at 11:00 US Eastern Standard Time. Location: at Bone Biologics Corporation offices, 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803 Burlington United States Agenda: To elect five directors to Board of Directors; to approve, in an advisory (non-binding) vote, our executive officer compensation; to ratify the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year ending December 31, 2022; and to transact any other business as may properly come before the meeting or at any adjournment thereof.
분석 기사 • Mar 18We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Bruce Stroever was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.